NCT06787118View on ClinicalTrials.gov

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIHR+ Breast CancerAI-related Musculoskeletal Pain
Interventions
DRUG

CBD oil

Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.

DRUG

Placebo

Patients will receive placebo for a total of 12 weeks.

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER